Skip to main content
Lupus Science & Medicine logoLink to Lupus Science & Medicine
. 2020 May 7;7(1):e000354corr1. doi: 10.1136/lupus-2019-000354corr1

Correction: First use of cenerimod, a selective S1P1 receptor modulator, for the treatment of SLE: a double-blind, randomised, placebo-controlled, proof-of-concept study

PMCID: PMC7228551  PMID: 32381629

Hermann V, Batalov A, Smakotina S, et al. First use of cenerimod, a selective S1P1 receptor modulator, for the treatment of SLE: a double-blind, randomised, placebo-controlled, proof-of-concept study. Lupus Science & Medicine 2019;6:e000354. doi: 10.1136/lupus-2019-000354.

The authors want to alert the readers to the error identified in Supplementary file 7.

The original Supplementary file 7 included the number of patients (n) in the full analysis set for each cenerimod dosage. The revised file has been amended to show the correct n numbers, which is the number of patients included in the modified pharmacodynamics set (mPD set).


Articles from Lupus Science & Medicine are provided here courtesy of BMJ Publishing Group

RESOURCES